Translational PK–PD for targeted protein degradation

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works

Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity

Hopfield, J. J. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.10.4135 · Cited by 1,594 · see citing works

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · see citing works

A Comprehensive Mathematical Model for Three-Body Binding Equilibria

Douglass, E. F., Miller, C. J., Sparer, G., Shapiro, H., & Spiegel, D. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja311795d · Cited by 472 · see citing works

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Cromm, P. M., & Crews, C. M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 423 · see citing works

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419 · see citing works

SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate

Roy, M. J., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K., & Ciulli, A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00092 · Cited by 386 · see citing works

Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action

Riching, K. M., Mahan, S. D., Corona, C. R., McDougall, M. G., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 307 · see citing works

Targeted protein degradation: A promise for undruggable proteins

Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 291 · see citing works

Structure‐Based Design of a Macrocyclic PROTAC

Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., & Ciulli, A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914396 · Cited by 251 · see citing works

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Mares, A., Miah, A. H., Smith, I. E. D., Rackham, M., Thawani, A. R., Cryan, J., Haile, P. A., Votta, B. J., Beal, A. M., Capriotti, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0868-6 · Cited by 232 · see citing works

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

Guo, W., Qi, X., Yu, X., Liu, Y., Chung, C.-I., Bai, F., Lin, X., Lu, D., Wang, L., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17997-6 · Cited by 220 · see citing works

Efficient targeted degradation via reversible and irreversible covalent PROTACs

Gabizon, R., Shraga, A., Gehrtz, P., Livnah, E., Gurwicz, N., Avram, L., Unger, T., Albeck, S., Shulman, Z., & London, N. (2020) · doi:10.26434/chemrxiv.11494398.v1 · Cited by 213 · see citing works

Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development

Derendorf, H., Lesko, L. J., Chaikin, P., Colburn, W. A., Lee, P., Miller, R., Powell, R., Rhodes, G. R., Stanski, D. R., & Venitz, J. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001211 · Cited by 207 · see citing works

The role of reversible and irreversible covalent chemistry in targeted protein degradation

Kiely‐Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 156 · see citing works

Targeted protein degradation and the enzymology of degraders

Fisher, S. L., & Phillips, A. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.004 · Cited by 126 · see citing works

Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs

Law, R. P., Nunes, J., Chung, C., Bantscheff, M., Buda, K., Dai, H., Evans, J. P., Flinders, A., Klimaszewska, D., Lewis, A. J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109237 · Cited by 121 · see citing works

Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes

Schiemer, J., Horst, R., Meng, Y., Montgomery, J. I., Xu, Y., Feng, X., Borzilleri, K., Uccello, D. P., Leverett, C., Brown, S., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00686-2 · Cited by 113 · see citing works

History and Future Perspectives on the Discipline of Quantitative Systems Pharmacology Modeling and Its Applications

Azer, K., Kaddi, C. D., Barrett, J. S., Bai, J. P. F., McQuade, S. T., Merrill, N. J., Piccoli, B., Neves, S. R., Marchetti, L., Lombardo, R., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.637999 · Cited by 85 · see citing works

The rise and rise of protein degradation: Opportunities and challenges ahead

Hughes, S. J., Testa, A., Thompson, N., & Churcher, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.006 · Cited by 83 · see citing works

Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations

Watt, G. F., Scott‐Stevens, P., & Gaohua, L. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.02.005 · Cited by 72 · see citing works

A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands

Han, B. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014715 · Cited by 72 · see citing works

The Benzoquinone Ansamycin Geldanamycin Stimulates Proteolytic Degradation of Focal Adhesion Kinase

Ochel, H.-J., Schulte, T. W., Nguyen, P., Trepel, J. B., & Neckers, L. (1999) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1998.2774 · Cited by 69 · see citing works

A kinetic proofreading model for bispecific protein degraders

Bartlett, D. W., & Gilbert, A. M. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09722-z · Cited by 37 · see citing works

Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms

Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30 · see citing works

Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation

Riching, K. M., Vasta, J. D., Hughes, S. J., Zoppi, V., Maniaci, C., Testa, A., Urh, M., Ciulli, A., & Daniels, D. L. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100009 · Cited by 25 · see citing works

Examining Targeted Protein Degradation from Physiological and Analytical Perspectives: Enabling Translation between Cells and Subjects

Daurio, N. A., Zhou, H., Chen, Y., Sheth, P. R., Imbriglio, J. E., McLaren, D. G., Tawa, P., Rachdaoui, N., Previs, M. J., Kasumov, T., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00380 · Cited by 12 · see citing works

Protein degraders enter the clinic — a new approach to cancer therapy

Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658 · see citing works

Targeted protein degradation: advances in drug discovery and clinical practice

Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326 · see citing works

Targeted protein degradation for cancer therapy

Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 245 · see citing works

Proximity-Based Modalities for Biology and Medicine

Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 205 · see citing works

Targeted protein degrader development for cancer: advances, challenges, and opportunities

Fang, Y., Wang, S., Han, S., Zhao, Y., Yu, C., Liu, H., & Li, N. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.003 · Cited by 110 · see citing works

Delivering on the promise of protein degraders

O’Brien, M. N., Luthra, S. A., Brown, M. F., & Bartlett, D. W. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00652-2 · Cited by 108 · see citing works

The rise of degrader drugs

Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 67 · see citing works

Confounding Factors in Targeted Degradation of Short-Lived Proteins

Vetma, V., Perez, L. C., Eliaš, J., Stingu, A., Kombara, A., Gmaschitz, T., Braun, N., Ciftci, T., Dahmann, G., Diers, E., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00152 · Cited by 53 · see citing works

Clinical Translation of Targeted Protein Degraders

Kong, N. R., & Jones, L. H. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2985 · Cited by 51 · see citing works

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)

Haid, R. T. U., & Reichel, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010195 · Cited by 49 · see citing works

Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence

Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50 · see citing works

Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation

Zang, R., Barth, A., Wong, H., Mařı́k, J., Shen, J., Lade, J. M., Grove, K. J., Durk, M. R., Parrott, N. J., Rudewicz, P. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00502 · Cited by 37 · see citing works

Current strategies for improving limitations of proteolysis targeting chimeras

Pu, C., Wang, S., Liu, L., Feng, Z., Zhang, H., Gong, Q., Sun, Y., Guo, Y., & Li, R. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107927 · Cited by 29 · see citing works

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 27 · see citing works

DegraderTCM: A Computationally Sparing Approach for Predicting Ternary Degradation Complexes

Rossetti, P., Apprato, G., Caron, G., Ermondi, G., & Sebastiano, M. R. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00362 · Cited by 19 · see citing works

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Taylor, J. D., Barrett, N., Cuesta, S. M., Cassidy, K. B., Pachl, F., Dodgson, J., Patel, R. J., Eriksson, T. M., Riley, A., Burrell, M. R., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06803-4 · Cited by 19 · see citing works

An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions

Guzzetti, S., & Gutierrez, P. M. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09857-9 · Cited by 18 · see citing works

Design, synthesis, and biological evaluation of RSL3-based GPX4 degraders with hydrophobic tags

Ning, Y., Zhu, Z., Wang, Y., Fan, X., Wang, J., Qian, H., Qiu, X., & Wang, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116719 · Cited by 17 · see citing works

Development of PROTACS degrading KRAS and SOS1

Hamilton, G., Eggerstorfer, M.-T., & Stickler, S. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.051653 · Cited by 16 · see citing works

EFMC: Trends in Medicinal Chemistry and Chemical Biology

Auberson, Y. P., Arimondo, P. B., Duca, M., Essig, S., Grether, U., Rufer, A. C., Sbardella, G., Schopfer, U., Torrens, A., van der Stelt, M., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202200690 · Cited by 16 · see citing works

Quantitative Measurement of Rate of Targeted Protein Degradation

Lynch, T. L., Marin, V. L., McClure, R. A., Phipps, C. J., Ronau, J. A., Rouhimoghadam, M., Adams, A. M., Kandi, S., Wolke, M. L., Shergalis, A. G., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00262 · Cited by 14 · see citing works

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673

Wu, Y. H., Meibohm, B., Zhang, T., Hou, X., Wang, H., Sun, X., Jiang, M., Zhang, B., Zhang, W., Liu, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17332 · Cited by 14 · see citing works

Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers

Zhang, W., Li, Y., Zhou, M.-M., & Zeng, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.09.006 · Cited by 13 · see citing works

Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling

Haid, R. T. U., & Reichel, A. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3273 · Cited by 12 · see citing works

PK/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows

Haid, R. T. U., & Reichel, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104311 · Cited by 14 · see citing works

Application of Mechanistic Multiparameter Optimization and Large-Scale In Vitro to In Vivo Pharmacokinetics Correlations to Small-Molecule Therapeutic Projects

Broccatelli, F., Veeravalli, V., Cashion, D. K., Baylon, J. L., Lombardo, F., & Jia, L. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00256 · Cited by 11 · see citing works

In situ construction of intracellular supramolecular assemblies as an alternative strategy for protein degradation

Hu, X., Yao, Q., Wu, X., Chen, J., Zhang, R., Zhao, Y., & Gao, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-61175-5 · Cited by 10 · see citing works

The 17 th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders

Ciulli, A., O’Connor, S., Chung, C., Hartung, I. V., Testa, A., Daniels, D. L., & Heitman, L. H. (2023) · ChemMedChem · doi:10.1002/cmdc.202300464 · Cited by 9 · see citing works

Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance

Peng, R., Liu, X., Chen, C., Guo, R., & Min, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00961d · Cited by 8 · see citing works

Quantum Mechanics-Based Ranking of Predicted Proteolysis Targeting Chimeras-Mediated Ternary Complexes

Monteleone, S., Morao, I., Fedorov, D. G., & Kellici, T. F. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00534 · Cited by 5 · see citing works

To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives

Castagna, D., Gourdet, B., Hjerpe, R., MacFaul, P., Novak, A., Révol, G., Rochette, É., & Jordan, A. M. (2024) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2024.07.002 · Cited by 5 · see citing works

Inducing Receptor Degradation as a Novel Approach to Target CC Chemokine Receptor 2 (CCR2)

Zacarı́as, N. V. O., Röth, S., Broekhuis, J. D., van der Es, D., Moreau, K., & Heitman, L. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168984 · Cited by 5 · see citing works

Comparison of Tumor Binding Across Tumor Types and Cell Lines to Support Free Drug Considerations for Oncology Drug Discovery

Jordan, S., Ryu, S., Burchett, W., Davis, C. D., Jones, R. D. O., Zhang, S., Zueva, L., Chang, G., & Di, L. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.024 · Cited by 3 · see citing works

Targeted protein degradation: bridging chemical biology and clinical translation

Zhang, Y., Fu, J.-W., Liu, Y., Wu, R. Y., Liang, Y., Zhang, W., Yuan, T., Zhu, H., He, Q.-J., & Yang, B. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01861-2 · Cited by 2 · see citing works

Emerging pharmacology of targeted protein degraders

Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2 · see citing works

Computational approaches to aid PROTAC drug discovery

Chakraborti, S., & McAulay, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00004-2 · Cited by 1 · see citing works

Proteolysis-targeting Chimera efficacy prediction using a deep-learning–QSP model

Goo, S., Kim, J., Lee, S., Jung, S., Chae, J., Choi, J.-M., & Yun, H. (2026) · Journal of Cheminformatics · doi:10.1186/s13321-026-01152-2 · Cited by 1 · see citing works

Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti‐Infectives

Rox, K. (2026) · ChemMedChem · doi:10.1002/cmdc.202500743 · Cited by 1 · see citing works

A mechanistic pharmacokinetic-pharmacodynamic model for degrader-antibody conjugates

Balthasar, M. P., & Bartlett, D. W. (2026) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-10016-5 · Cited by 1 · see citing works

Drug–Drug Interaction Prediction Using SMOTE and Gray Wolf Optimizer: Comparative Analysis of Machine Learning and Deep Learning Models

Elsharkawy, B., Abdelatey, A., Elbarbary, O. G., Abdelkader, H. M., & Mahmoud, N. (2026) · Information · doi:10.3390/info17050467 · Cited by 1 · see citing works

Application of mechanistic multiparameter optimization and large scale in vitro to in vivo pharmacokinetics correlations to small molecule therapeutic projectsPreprint

Broccatelli, F., Veeravalli, V., Cashion, D. K., Baylon, J. L., Lombardo, F., & Jia, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.06.583780 · Cited by 1 · see citing works

Research and Implementation of Drug Relocation Algorithm Based on Deep Learning

Zhang, H., Tao, R., Yueqi, L., Yuqing, W., Jiacheng, X., Yuxuan, H., Chen, L., & Xiangxin, G. (2024) · International Conference on Computer and Automation Engineering · doi:10.1109/iccae59995.2024.10569441

Quantifying protein kinetics in vivo: influence of precursor dynamics on product labeling

Yao, H., Kelley, S., Zhou, D., VanSickle, S., Wang, S., Piesvaux, J., Zhou, H., Chen, H., McKenney, D., McLaren, D. G., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2024

The next frontier in drug discovery: Unveiling the pharmacological potential of proximity inducers

Holmberg‐Douglas, N., Keenan, K. N., de Turiso, F. G.-L., Chekler, E. P., Shanmugasundaram, V., Riggs, J. R., & Zapf, C. W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00018-2

Hitting a Moving Target

Chen, E. P. (2025) · Wiley eBooks · doi:10.1002/9781119650263.ch11

PKPD modeling and in silico models

Pehrson, R., Winiwarter, S., Subramanian, V., Mogemark, M., & Miljković, F. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00022-4

NAVIGATING CHALLENGES IN ORAL HETEROBIFUNCTIONAL DEGRADERS: INSIGHTS AND STRATEGIES FOR EARLY-STAGE PROJECTS

Güney, T., Tran, A. T., & Stamp, K. (2025) · Medicinal chemistry reviews · doi:10.1021/mc-2025-vol60.ch18

Biomarker-Driven Computational PK/PD Modeling and Dosing Optimization of the Targeted Protein Degrader Fulvestrant in Estrogen Receptor–Positive Breast CancerPreprint

Srinivasan, N. (2025) · Research Square · doi:10.21203/rs.3.rs-8227309/v1

OPTIMIS: Optimizing Personalized Therapies through Integrated Multiscale Intelligent SimulationPreprint

Su, Z., & Wu, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.24.713941

Divergent effects of target protein stabilisation versus overproduction on PROTAC activityPreprint

Gudauskaite, E., Moran, B. H., Taylor, G. C. A., & Wood, A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.15.718695

Targeted Nano-delivery of Recombinant Therapeutic Cargos for Ovarian Cancer: Advances in Molecular Pharmacodynamics and Pharmacokinetics

Chandrakar, O., Satapathy, T., Sahu, P., & Sahu, K. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10672-1

Oncogene activation mechanism determines the limits of targeted protein degradation

Gudauskaite, E., Hernández-Morán, B. A., Taylor, G. C. A., & Wood, A. J. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.08.006

Revisiting Fulvestrant Dosing: Biomarker-Driven Mathematical PK/PD Modeling and Dosing Optimization in Estrogen Receptor–Positive Breast Cancer

Srinivasan, N. (2026) · Mathematical Biosciences · doi:10.1016/j.mbs.2026.109805

Aptamer-Based Heterobifunctional Targeted Degraders in Disease Treatment

Liang, X., Du, M., Wang, J., Lei, X., Tian, Y., & Zhang, X. (2026) · Molecules · doi:10.3390/molecules31183318

Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states

Wang, T., Ji, C., & Zhao, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1967704

Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK / PD Modeling

Haid, R. T. U., & Reichel, A. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3273 · Cited by 12 · see citing works

Translational Pharmacokinetic-Pharmacodynamic Modeling Framework for Protein Degraders in Oncology Drug DiscoveryPreprint

Fonsi, M., Ramakrishnan, R., & McGinnity, D. F. (2026) · Research Square · doi:10.21203/rs.3.rs-9608343/v1

PK/PD Modeling of Targeted Protein Degraders

Haid, R. T. U. (2025) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-b-000724521

PK/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows

Haid, R. T. U., & Reichel, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104311 · Cited by 14 · see citing works

Targeted Protein Degraders (TPD): PK/PD translation from preclinical to clinical

Chen, D. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2025.101085